Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Rapid Dose Therapeutics's Enterprise Value is $13.51 Mil.
Rapid Dose Therapeutics's EBIT for the trailing twelve months (TTM) ended in Nov. 2025 was $-2.19 Mil. Therefore, Rapid Dose Therapeutics's EV-to-EBIT ratio for today is -6.18.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Rapid Dose Therapeutics (OTCPK:RDTCF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Rapid Dose Therapeutics's current Enterprise Value is $13.51 Mil.
Rapid Dose Therapeutics's EBIT for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.19 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Rapid Dose Therapeutics's EV-to-EBITDA for today is:
Rapid Dose Therapeutics's current Enterprise Value is $13.51 Mil.
Rapid Dose Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86 Mil.
Rapid Dose Therapeutics's current Enterprise Value is $13.51 Mil.
Rapid Dose Therapeutics's Revenue for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.99 Mil.
Rapid Dose Therapeutics's current Enterprise Value is $13.51 Mil.
Rapid Dose Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.69 Mil.
Rapid Dose Therapeutics's current Enterprise Value is $13.51 Mil.
Rapid Dose Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Dose Therapeutics Enterprise Value Related Terms
Rapid Dose Therapeutics Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDTCF vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Rapid Dose Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's Enterprise Value falls into.
Rapid Dose Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Rapid Dose Therapeutics's Enterprise Value for the fiscal year that ended in Feb. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Dose Therapeutics (RDTCF) has a Enterprise Value of $13.51 Mil as of Jul. 08, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Rapid Dose Therapeutics and its competitors.
Is Rapid Dose Therapeutics' Enterprise Value too high?
Rapid Dose Therapeutics' current Enterprise Value is $13.51 Mil. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Enterprise Value compare to VRTX and REGN?
Rapid Dose Therapeutics' Enterprise Value of $13.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current Enterprise Value is $13.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current Enterprise Value is $13.51 Mil. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Enterprise Value is $13.51 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued.
The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30.
GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.
Key valuation signals for RDTCF:
Enterprise Value: $13.51 Mil
GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score
Get the complete analysis for RDTCF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
